Use of adenosine aspartate for the preparation of pharmaceutical products for the treatment of liver cancer
AssigneeUniversidad Nacional Autonnoma de Mexico
InventorsVictoria-Eugenia Chagoya-Hazas, Rolando-Efraín Hernandez Muñoz, Saúl Villa-Treviño
Life of this patent
Estimating the term…
Abstract
The present invention relates to the novel use of an adenosine aspartate product for the formulation of a drug intended to prevent the development of preneoplastic lesions and to reverse some types of cancer, particularly liver cancer, providing chemoprotection, preventing myelotoxic effects.
Claims7
A method of inhibiting the outgrowth of preneoplastic lesions of the liver, which comprises administering to a patient in need thereof a therapeutically effective amount of adenosine aspartate, wherein the patient is not suffering from cirrhosis of the liver.
A method of inhibiting the outgrowth of preneoplastic lesions of the liver, which comprises administering to a patient in need thereof a therapeutically effective amount of adenosine aspartate, wherein the adenosine aspartate is administered at a dose of 750 mg per day.
Dependencies are inferred from the claim text.